Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696

OBJECTIVES: The combined neprilysin/rennin-angiotensin system inhibitor sacubitril/valsartan (LCZ696) has shown its superiority over ACEI/ARB therapy. In view of the existing concern of its adverse effects, we aimed to provide evidence of the safety of the new drug. RESULTS: A total of 6 randomized...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Li, Bo, Zhao, Yunhe, Yin, Bo, Helian, Mengfei, Wang, Xinmei, Chen, Feng, Zhang, Hongxia, Sun, Hui, Meng, Bin, An, Fengshuang
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2017
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669972/
https://ncbi.nlm.nih.gov/pubmed/29137346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18312
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы